Page 16 - 80 guidelines for the treatment of malaria_opt
P. 16

nd
              Guidelines for the treatment of malaria – 2  edition


               regions), and in epidemics and complex emergency situations; and
            ■  severe malaria.

            The guidelines provide a framework for the development of specific and more detailed
            national treatment protocols that take into account local antimalarial drug resistance
            patterns and health service capacity in the country (see Annex 2). They are not intended
            to provide, or to be used, as a comprehensive clinical management guide/manual for the
            treatment of malaria.

            1.2.2  Target audience

            These guidelines are primarily targeted at policy-makers in ministries of health, who
            formulate country specific treatment guidelines. However, the following groups should
            also find them useful:
            ■  public health and policy specialists working in hospitals, research institutions, medical
               schools, nongovernmental organizations and agencies working as partners in health or
               malaria control, the pharmaceutical industry and primary health-care services; and
            ■  health professionals (doctors, nurses and paramedical officers).



            1.3  methods used in developing the guidelines and recommendations

            In the first edition of the WHO Guidelines for the treatment of malaria (2006), the
            methodology for identifying the questions, search and review of evidence is similar to
            that used in this current update. However, the Grading of Recommendations Assessment,
            Development and Evaluation (GRADE) methodology was not applied then, rather in
            formulating recommendations, evidence was graded in order of priority as follows:
            ■  formal systematic reviews, such as Cochrane reviews, including more than one
               randomized control trial;
            ■  comparative trials without formal systematic review;
            ■  observational studies (e.g. surveillance, pharmacological data);
            ■  expert opinion/consensus.

            Since the release of the first edition of the guidelines, the WHO’s standard methods
            for guidelines development has evolved and, thus, this second edition was developed
            in accordance with the updated WHO standard methods for guideline development.
            This methodology incorporates a transparent link between research evidence and
            recommendations. The GRADE system, which has been incorporated into this update,
            is a uniform approach that is being widely adopted. It employs explicit methods,
            developed by the GRADE Working Group, to formulate and to evaluate the strength of
            a recommendation based on the robustness of the evidence relating to a specific clinical
            question. For this second edition of the guidelines, only new recommendations have been
            subjected to the GRADE process (see Annex 1).
     2
   11   12   13   14   15   16   17   18   19   20   21